KTF Investments LLC Makes New Investment in AbbVie Inc. $ABBV

Key Points

• KTF Investments LLC established a new stake of 5,805 shares (~$1.33M) in AbbVie during Q4, while institutional investors collectively own about 70.23% of the company.
• AbbVie’s consensus rating is a “Moderate Buy” with an average price target of $253.19, and recent analyst actions have produced targets ranging roughly from $240 to $275.
• Company insiders have been sizable net sellers recently—SVP David Ryan Purdue sold 5,230 shares (~$1.22M) and EVP Perry C. Siatis sold 22,381 shares (~$5.15M)—leaving just 0.06% insider ownership.

KTF Investments LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,805 shares of the company's stock, valued at approximately $1,326,000.

Several other institutional investors have also recently bought and sold shares of ABBV. Chelsea Counsel Co. acquired a new position in AbbVie during the third quarter worth $26,000. Westend Capital Management LLC acquired a new position in AbbVie during the fourth quarter worth $29,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie during the third quarter worth $31,000. WestEnd Advisors LLC raised its holdings in AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock worth $32,000 after buying an additional 85 shares during the last quarter. Finally, Caitlin John LLC acquired a new position in AbbVie during the third quarter worth $33,000. Institutional investors and hedge funds own 70.23% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ABBV. William Blair reiterated an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. Cantor Fitzgerald reduced their target price on shares of AbbVie from $250.00 to $240.00 and set an "overweight" rating for the company in a research note on Wednesday, April 8th. Guggenheim upped their target price on shares of AbbVie from $242.00 to $249.00 and gave the stock a "buy" rating in a research note on Friday, April 10th. Barclays began coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an "overweight" rating and a $275.00 target price for the company. Finally, Piper Sandler reduced their target price on shares of AbbVie from $299.00 to $294.00 and set an "overweight" rating for the company in a research note on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $253.19.

Insider Activity

In related news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Stock Performance

ABBV opened at $197.24 on Tuesday. The firm has a market cap of $348.76 billion, a P/E ratio of 83.58, a PEG ratio of 0.71 and a beta of 0.38. The firm has a 50-day moving average of $215.99 and a 200 day moving average of $222.03. AbbVie Inc. has a fifty-two week low of $176.57 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm's revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts predict that AbbVie Inc. will post 14.21 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.5%. AbbVie's dividend payout ratio is presently 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie filed for U.S. approval to add a subcutaneous (SC) induction option for SKYRIZI (risankizumab‑rzaa) in adults with moderately to severely active Crohn’s disease — if approved this would expand an existing high‑value asset into an additional, large indication and could boost near‑term revenue visibility. AbbVie Submits Regulatory Application to FDA for SKYRIZI (risankizumab-rzaa) Subcutaneous Induction
• Positive Sentiment: AbbVie’s planned >$1B research campus in the Research Triangle signals meaningful reinvestment in R&D and expansion of its life‑sciences footprint — a positive for long‑term innovation capacity and local talent access. AbbVie's Planned $1B-Plus Research Triangle Campus Development Buoys Improved Life Sciences Outlook
• Positive Sentiment: EvolveImmune announced a preclinical milestone and nomination of a development candidate under its collaboration with AbbVie — incremental pipeline news that reinforces partnership activity and early-stage oncology optionality. EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
• Positive Sentiment: Analyst and retail commentary continue to flag AbbVie as a strong dividend name, supporting yield/income investor interest and underpinning the stock during volatile biotech news cycles. AbbVie (ABBV) Maintains Dividend Strength as Core Drugs Drive Cash Flow
• Neutral Sentiment: AbbVie is set to report Q1 earnings imminently; the market will focus on topline trends for Humira/Skyrizi/oncology, margin commentary and FY guidance — analysts’ previews set expectations but the reaction will hinge on guidance. AbbVie (ABBV) to report earnings tomorrow: Here is what to expect Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts?
• Negative Sentiment: AbbVie received a Complete Response Letter (CRL) from the FDA for its trenibotulinumtoxinE BLA, citing manufacturing issues — a regulatory setback that delays potential revenue from a wrinkle treatment and raises near‑term uncertainty. AbbVie Inc. (ABBV) Receives CRL from the FDA About the Biologics License Application for trenibotulinumtoxinE FDA rejects AbbVie wrinkle treatment application over manufacturing issues
• Negative Sentiment: Data from Oruka Therapeutics’ experimental psoriasis therapy has drawn attention as a potential competitive threat to AbbVie’s large dermatology franchise (~$18B) — watch market share risk if Oruka’s data advance to approvals. How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.